FASBAT is an observational extension to the EDNA study.
The EDNA study is recruiting patients newly diagnosed with “wet” (or neovascular) age-related macular degeneration. The study will collect information on how good various tests are in detecting the first signs of development of wet AMD.
Wet AMD is a condition which occurs in the macula (the centre part of the retina of the eye) which can cause irreversible sight loss if not treated quickly, therefore detecting it early so that treatment can be started as soon as possible is important to help prevent loss of sight.
The aim of the FASBAT study is to follow participants who have been recently diagnosed with wet AMD.
Patients who are eligible to take part in FASBAT will already be participating in EDNA and will be approached by the local research team when they attend hospital for their routine clinic appointment.
The FASBAT study is funded by Novartis and York Teaching Hospitals NHS Foundation trust is acting as study Sponsor.
The study is currently recruiting; opening in April 2016 and will run until September 2022 approximately.
If you would like more information about the study please contact the study office at York Teaching Hospitals NHS Foundation Trust 01904 725129 or email FASBAT@york.nhs.uk.